Pfizer starts late-stage trial of mRNA-based flu vaccine

Pfizer starts late-stage trial of mRNA-based flu vaccine Pfizer Inc said on Wednesday it had started a late-stage U.S. trial of an influenza vaccine involving 25,000 patients, among the first such studies for a messenger RNA flu shot. Reuters Reuters

...

The company said that the first participants had been dosed with the vaccine, which is based on the same technology used in its widely-used COVID-19 shot developed in partnership with Germanay's BioNTech SE (22UAy.DE).

...